Should MMF treatment be the first-line therapy in autoimmune hepatitis?

This study shows that MMF treat ment in naive patients is superior to AZA in terms of both efficacy and tolerability. This study raises a number of questions. Firstly, only 48% of patients in both groups had a compatible but non-typical diagnosis of autoimmune hepatitis.

Source: Journal of Hepatology - February 23, 2024 Category: Gastroenterology Authors: Laurent Alric Tags: Letter to the Editor Source Type: research